Medtronic plc (MDT) Debt to Assets Ratio: 0.00%
The debt to assets ratio for Medtronic plc (MDT) is 0.00% as of Wednesday, June 10, 2026.
MDT Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.00%
MDT Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Medtronic plc (MDT) | $103.04B | 0.00% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 0.15% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 0.52% |
| Elevance Health Inc. (ELV) | $87.43B | 0.27% |
| CVS Health Corporation (CVS) | $125.16B | 0.36% |
| Cigna Corporation (CI) | $78.25B | 0.20% |
| Danaher Corporation (DHR) | $130.25B | 0.22% |
| Regeneron Pharmaceuticals, Inc. (REGN) | $62.59B | 0.07% |
| Pfizer Inc. (PFE) | $146.36B | 0.32% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 0.01% |
Leverage Ratios Comparison
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
0.00
Interest Coverage
9.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Medtronic plc Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medtronic plc Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Medtronic plc (MDT)?
- The debt to assets ratio for MDT stock is 0.00%.
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha